In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA clears IDev's biliary stent delivery system

This article was originally published in Clinica

Executive Summary

IDev Technologies' Supera Veritas transhepatic biliary system has received 510(k) clearance from the US FDA. The product is a next-generation delivery system for the firm's Supera biliary stent, which has been available in the US since 2006 for the palliative treatment of obstructions in the bile duct caused by malignant neoplasms. Supera Veritas makes deploying the stent easier and more precise, Webster, Texas-based IDev says. The firm plans to launch the delivery system in the first quarter of next year. Supera Veritas is also being evaluated along with the Supera stent in an ongoing US trial in patients with peripheral arterial disease of the superficial femoral artery.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts